Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study

Wernich Thomsen, Reimar; Pedersen, Lars; Møller, Niels; Kahlert, Johnny; Beck-Nielsen, Henning; Toft Sørensen, Henrik
June 2015
Diabetes Care;Jun2015, Vol. 38 Issue 6, p1089
Academic Journal
OBJECTIVE To investigate whether the use of incretin-based drugs (GLP-1 receptor agonists, and dipeptidyl peptidase 4 [DPP4] inhibitors) is associated with acute pancreatitis. RESEARCH DESIGN AND METHODS The study was a nationwide population-based case-control study using medical databases in Denmark. Participants were 12,868 patients with a first-time hospitalization for acute pancreatitis between 2005 and 2012 and a population of 128,680 matched control subjects. The main outcome measure was the odds ratio (OR) for acute pancreatitis associated with different antihyperglycemic drugs. We adjusted for history of gallstones, alcoholism, obesity, and other pancreatitis-associated comorbidities and medications. RESULTS A total of 89 pancreatitis patients (0.69%) and 684 control subjects (0.53%) were ever users of incretins. The crude OR for acute pancreatitis among incretin users was 1.36 (95% CI 1.08-1.69), while it was 1.44 (95% CI 1.34-1.54) among users of other antihyperglycemic drugs. After confounder adjustment, the risk of acute pancreatitis was not increased among incretin users (OR 0.95 [95% CI 0.75-1.21]), including DPP4 inhibitor users (OR 1.04 [95% CI 0.80-1.37]) or GLP-1 receptor agonist users (OR 0.82 [95% CI 0.54-1.23]), or among nonincretin antihyperglycemic drug users (OR 1.05 [95% CI 0.98-1.13]), compared with nonusers of any antihyperglycemic drugs. Findings were similar in current versus ever drug users, and in patients with pancreatitis risk factors. The adjusted OR comparing incretin-based therapy with other antihyperglycemic therapy internally while also adjusting for diabetes duration and complications was 0.97 (95% CI 0.76-1.23). CONCLUSIONS Our findings suggest that the use of incretin-based drugs appears not to be associated with an increased risk of acute pancreatitis.


Related Articles

  • Safety and Tolerability of the Treatment of Youth-Onset Type 2 Diabetes.  // Diabetes Care;Jun2013, Vol. 36 Issue 6, p1765 

    OBJECTIVE--Data related to the safety and tolerability of treatments for pediatric type 2 diabetes are limited. The TODAY clinical trial assessed severe adverse events (SAEs) and targeted nonsevere adverse events (AEs) before and after treatment failure, which was the primary outcome (PO)....

  • Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Leung, Lawrence; Birtwhistle, Richard; Kotecha, Jyoti; Hannah, Susan; Cuthbertson, Sharon // British Journal of Nutrition;2009, Vol. 102 Issue 12, p1703 

    It has been estimated that up to one-third of patients with diabetes mellitus use some form of complementary and alternative medicine. Momordica charantia (bitter melon) is a popular fruit used for the treatment of diabetes and related conditions amongst the indigenous populations of Asia, South...

  • In This Issue of Diabetes Care. Resnick, Helaine E. // Diabetes Care;Oct2014, Vol. 37 Issue 10, p2663 

    The article discusses various reports published within this issue including one on a study on the effect of albiglutide on diabetic patients, one on the importance of HbA testing to patients with diabetes and one on the effect of fetal hyperglycemia exposure on patients with gestational diabetes...

  • Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY.  // Diabetes Care;Jun2013, Vol. 36 Issue 6, p1749 

    OBJECTIVE--The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that combination therapy with metformin plus rosiglitazone provided superior durability of glycemic control compared with metformin alone, with significantly lower treatment failure rates...

  • Erratum.  // Diabetes;Jun2014, Vol. 63 Issue 6, p2183 

    A correction to the article "Incretin Therapy and Pancreatic Pathologies: Background Pathology Versus Drug-Induced Pathology in Rats," that appeared in the 2014 issue of "Diabetes" is presented.

  • Drug Interactions of Medications Commonly Used in Diabetes. Triplitt, Curtis // Diabetes Spectrum;Fall2006, Vol. 19 Issue 4, p202 

    The article discusses drug interactions of medications commonly used in diabetes. Medications used in diabetes that become appropriate therapy include medications for dyslipidemia, hypertension, antiplatelet therapy and glycemic control. Minimizing the risk for drug interactions should be a goal...

  • Smoke or Fire? Acute Pancreatitis and the Liraglutide Trials. Gale, Edwin A. M. // Diabetes Care;Jun2015, Vol. 38 Issue 6, p948 

    The article offers insights on two studies examining pancreatitis and incretin-based therapies published in this issue of the journal. Particular focus is given to the debate surrounding the link between acute pancreatitis and incretin-based drugs. Also mentioned are the possible shared effect...

  • Pancreatitis Associated With Incretin-Based Therapies. IYER, SHRIDHAR N.; TANENBERG, ROBERT J.; MENDEZ, CARLOS E.; WEST, R. LEE; DRAKE III, ALMOND J. // Diabetes Care;Apr20123, Vol. 36 Issue 4, pe49 

    The article reports on acute pancreatitis induced by incretin-based therapies such as glucagon-like peptide-1 agonists (GLP-1) and dipeptidyl peptidase-IV inhibitors (DPP-IV) for the treatment of type 2 diabetes. It relates that the U.S. Food and Drug Administration (FDA) has not given approval...

  • Pancreatitis in a child: case report.  // Reactions Weekly;2/26/2005, Issue 1040, p15 

    Discusses a case report on the development of pancreatitis in a boy while receiving risperidone for aggressive behaviour. Dosage of risperidone given to the child daily; Symptoms developed by the patient after four weeks of medication; Condition of the patient when he was admitted to the hospital.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics